علاج مرض ستيل الصعب العلاج في البالغين

References

DOI: 10.1136/ard-2024-225851

• A patient who fails to achieve CID off GC after IL-1/IL-6 inhibitor rotation should be considered as D2T and should be discussed in multidisciplinary rounds with an expert in Still's disease, for example, at a reference centre (in Europe through the ERN-RITA, https://ern-rita.org/); the use of less well-established therapeutic options should be discussed.
• These include JAK inhibitors, haematopoietic stem cell transplantation and immunosuppressants.
• Experimental therapy may include JAK inhibitors, emapalumab, bispecific antibody to IL-1/IL-18.